Our Services
Medical Information
Helpful Resources
Published on: 9/26/2026
Dozens of peptide drugs carry full FDA approval, including insulin and GLP-1 medications like semaglutide, liraglutide, and tirzepatide for type 2 diabetes and obesity, teriparatide and abaloparatide for osteoporosis, leuprolide and goserelin for prostate cancer and endometriosis, octreotide for acromegaly and neuroendocrine tumors, desmopressin for diabetes insipidus and bedwetting, glucagon for severe hypoglycemia, setmelanotide for rare genetic obesity, bremelanotide for hypoactive sexual desire disorder, and icatibant for hereditary angioedema. Popular "research" or wellness peptides such as BPC-157, CJC-1295, ipamorelin, and thymosin beta-4 are not FDA approved for any condition, and several have been flagged as unsafe for compounding. Approval status, dosing, and legitimate uses vary widely by peptide and by the condition being treated, so the distinctions matter more than the label "peptide" suggests; see below for the complete breakdown and the details you should weigh before starting anything.
If you are considering peptides because of symptoms like fatigue, slow healing, weight changes, low libido, or joint pain, the smarter first step is understanding what is actually driving those symptoms rather than guessing at a compound. A free, instant, online symptom check takes just a few minutes, uses your specific symptoms to surface likely causes, and points you toward the right type of clinician, so any treatment decision you make next is grounded in your real health picture instead of marketing claims.
Last reviewed for medical accuracy: 09/26/2026
Below is an overview of FDA approved peptides and their primary indications. If you have symptoms or concerns, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. Always speak to a doctor about anything that could be life-threatening or serious.
Peptide hormones play a vital role in regulating metabolism, blood sugar, and fluid balance.
Insulins (various analogs)
– Insulin lispro, aspart, glulisine, glargine, degludec, detemir
– Indication: Type 1 and Type 2 diabetes mellitus
– Action: Rapid- or long-acting blood sugar control
Pramlintide (Symlin®)
– Amylin analog
– Indication: Type 1 and Type 2 diabetes mellitus, adjunct to insulin
– Action: Slows gastric emptying, reduces post-prandial glucose
Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide
– GLP-1 receptor agonists
– Indication: Type 2 diabetes mellitus; some also approved for weight management (e.g., semaglutide)
– Action: Stimulate insulin release, reduce appetite
Desmopressin (DDAVP®)
– Vasopressin analog
– Indication: Central diabetes insipidus, nocturnal enuresis, von Willebrand disease, mild hemophilia A
– Action: Promotes water reabsorption in kidneys, increases clotting factor release
Teriparatide (Forteo®) and Abaloparatide (Tymlos®)
– PTH (parathyroid hormone) analogs
– Indication: Osteoporosis in high-risk patients
– Action: Stimulate bone formation
Calcitonin salmon (Miacalcin®)
– Calcitonin analog
– Indication: Osteoporosis, Paget’s disease of bone
– Action: Inhibits bone resorption
Teduglutide (Gattex®)
– GLP-2 analog
– Indication: Short bowel syndrome
– Action: Enhances intestinal absorption and mucosal growth
Therapies for growth disorders and HIV-related muscle wasting.
Somatropin (Genotropin®, Humatrope®, others)
– Recombinant human growth hormone
– Indication: Pediatric growth hormone deficiency, adult GH deficiency, Turner syndrome, chronic kidney disease, Prader-Willi syndrome
– Action: Stimulates growth, metabolism
Tesamorelin (Egrifta®)
– Growth hormone-releasing factor analog
– Indication: HIV-associated lipodystrophy
– Action: Reduces abdominal fat
Targeting bowel motility, secretion, and pain.
Linaclotide (Linzess®) and Plecanatide (Trulance®)
– Guanylate cyclase-C agonists
– Indication: Irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation
– Action: Increases fluid secretion in the intestine, accelerates transit
Nesiritide (Natrecor®)
– B-type natriuretic peptide analog
– Indication: Acute decompensated heart failure (limited use due to mixed outcomes)
– Action: Vasodilation, diuresis
Peptides that modulate pain signals or act on CNS receptors.
Ziconotide (Prialt®)
– N-type calcium channel blocker derived from cone snail toxin
– Indication: Severe chronic pain in patients intolerant of or refractory to other treatments
– Action: Blocks pain signal transmission in spinal cord
Octreotide (Sandostatin®), Lanreotide (Somatuline®), Pasireotide (Signifor®)
– Somatostatin analogs
– Indication: Acromegaly, carcinoid syndrome, Cushing’s disease (pasireotide)
– Action: Inhibit hormone secretion (GH, ACTH, serotonin)
Anticoagulants and agents for clotting disorders.
Bivalirudin (Angiomax®)
– Direct thrombin inhibitor (peptidic)
– Indication: Percutaneous coronary intervention
– Action: Prevents clot formation by inhibiting thrombin
Eptifibatide (Integrilin®)
– Glycoprotein IIb/IIIa inhibitor (cyclic heptapeptide)
– Indication: Acute coronary syndrome, percutaneous coronary intervention
– Action: Inhibits platelet aggregation
Enfuvirtide (Fuzeon®)
– HIV fusion inhibitor (36-amino-acid peptide)
– Indication: HIV-1 infection in treatment-experienced patients
– Action: Blocks viral entry into CD4 cells
Daptomycin (Cubicin®)
– Cyclic lipopeptide antibiotic
– Indication: Complicated skin infections, bacteremia, endocarditis (Staphylococcus aureus)
– Action: Disrupts bacterial cell membrane
Hormone analogs for fertility and sexual health.
Leuprolide (Lupron®), Goserelin (Zoladex®), Triptorelin (Trelstar®), Histrelin (Vantas®)
– GnRH agonists
– Indication: Prostate cancer, endometriosis, uterine fibroids, precocious puberty
– Action: Suppress gonadal steroid production after initial stimulation
Degarelix (Firmagon®), Relugolix (Orgovyx®)
– GnRH antagonists
– Indication: Advanced prostate cancer
– Action: Immediately blocks gonadotropin release, lowers testosterone
Bremelanotide (Vyleesi®)
– Melanocortin receptor agonist
– Indication: Hypoactive sexual desire disorder in premenopausal women
– Action: Modulates pathways in the brain related to sexual response
Various other applications in rare diseases or acute care.
Cosyntropin (Cortrosyn®)
– Synthetic ACTH analog (first 24 amino acids)
– Indication: Diagnostic test for adrenal insufficiency; off-label for infantile spasms
– Action: Stimulates cortisol release
Afamelanotide (Scenesse®)
– α-Melanocyte-stimulating hormone analog
– Indication: Erythropoietic protoporphyria
– Action: Increases melanin, reduces light sensitivity
Carbetocin (lonactin®)
– Oxytocin analog
– Indication: Prevention of uterine atony after cesarean delivery
– Action: Stimulates uterine contractions
If you’re experiencing new or worsening symptoms, it can help to do a free, online symptom check, using the doctor approved Ubie Symptom Checker. Always discuss any possible treatment or serious concern with your healthcare provider, especially if symptoms are severe or life-threatening.
(References)
* Davidson MB, Bate G, Kirkpatrick P. Exenatide. Nat Rev Drug Discov. 2005 Sep;4(9):713-4. doi: 10.1038/nrd1828. PMID: 16178120.
* Cines DB, Yasothan U, Kirkpatrick P. Romiplostim. Nat Rev Drug Discov. 2008 Nov;7(11):887-8. doi: 10.1038/nrd2741. PMID: 18974747.
* Sanz I, Yasothan U, Kirkpatrick P. Belimumab. Nat Rev Drug Discov. 2011 May;10(5):335-6. doi: 10.1038/nrd3436. PMID: 21532557.
* O'Neal R. Tesamorelin update. BETA. 2010 Summer-Fall;22(4):16-9. PMID: 21591600.
* Rudin CM. Vismodegib. Clin Cancer Res. 2012 Jun 15;18(12):3218-22. doi: 10.1158/1078-0432.CCR-12-0568. Epub 2012 Jun 7. PMID: 22679179; PMCID: PMC3715061.
* Koschker AC, Burger-Stritt S, Hahner S. [Hypoparathyroidism]. Dtsch Med Wochenschr. 2015 Aug;140(16):1195-7. doi: 10.1055/s-0041-102880. Epub 2015 Aug 11. PMID: 26261924.
* Przepiorka D, Ko CW, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu HJ, Gehrke BJ, Gomez-Broughton C, Kane RC, Kirshner S, Mehrotra N, Ricks TK, Schmiel D, Song P, Zhao P, Zhou Q, Farrell AT, Pazdur R. FDA Approval: Blinatumomab. Clin Cancer Res. 2015 Sep 15;21(18):4035-9. doi: 10.1158/1078-0432.CCR-15-0612. PMID: 26374073.
* Markham A, Keam SJ. Sotagliflozin: First Global Approval. Drugs. 2019 Jun;79(9):1023-1029. doi: 10.1007/s40265-019-01146-5. PMID: 31172412.
* Xu J, Pickard JM, Núñez G. FDA-approved disulfiram inhibits the NLRP3 inflammasome by regulating NLRP3 palmitoylation. Cell Rep. 2024 Aug 27;43(8):114609. doi: 10.1016/j.celrep.2024.114609. Epub 2024 Aug 7. PMID: 39116210; PMCID: PMC11398858.
* Kang C. Donanemab: First Approval. Drugs. 2024 Oct;84(10):1313-1318. doi: 10.1007/s40265-024-02087-4. Epub 2024 Sep 6. PMID: 39237715.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.